GLP-1

Patients

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

News

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.

R&D

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.

News

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.

News

The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.

News

Novo Nordisk data on obesity candidate CagriSema falls short of expectations, wiping around $94 billion off its market valuation.